Sumary of Empagliflozin yields clinical benefit in patients hospitalized with acute HF: EMPULSE:
- November 14, 2021 2 min read Source/Disclosures Published by: Source: Voors A, et al.
- LBS.05. Building on the Foundations of Treatment: Advances in Heart Failure Therapy.
- Presented at: American Heart Association Scientific Sessions;
- Disclosures: The EMPULSE trial was funded by Boehringer Ingelheim and Eli Lilly.
- Voors reports receiving research support and consultant fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Merck, Myokardia, Novo Nordisk, Novartis and Roche Diagnostics.
- Back to Healio In the EMPULSE trial, adults hospitalized with acute HF who received the SGLT2 inhibitor empagliflozin were 36% more likely than those on placebo to have clinical benefit at 90 days, including prevention of death and readmissions.
- Voors “Patients experienced improvements regardless of the type of heart failure — HF with reduced ejection fraction or HF with preserved ejection fraction, de novo or chronic decompensated heart failure — or whether they had diabetes or not,” Adriaan A.
- Voors, MD, cardiologist at University Medical Center Groningen in the Netherlands, said during a press conference at the American Heart Association Scientific Sessions.